Literature DB >> 15042000

The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas.

Russell R Broaddus1, Susu Xie, Ching-Ju Hsu, Jian Wang, Sui Zhang, Changping Zou.   

Abstract

OBJECTIVE: This study examined the effects of the chemopreventive agents 4-(N-hydroxyphenyl)retinamide (4-HPR) and alpha-difluoromethylornithine (DFMO) on leiomyoma growth. STUDY
DESIGN: Primary cultures of human uterine leiomyomas and matched normal myometrium were established from hysterectomy specimens. After treatment with 4-HPR, DFMO, or the combination 4-HPR plus DFMO, cell growth was analyzed. Apoptosis was quantified with the use of a flow cytometric terminal deoxynucleotidyl transferase-mediated fluorescein-deoxyuridine-triphosphate nick-end labeling assay. Protein extracts were analyzed with Western blot for p53, p21, and p16.
RESULTS: 4-HPR and DFMO inhibited the growth and induced apoptosis of leiomyoma cells, but not matched normal myometrial cells. Both 4-HPR and DFMO caused cells to accumulate at G0/G1, with a corresponding decrease in the S-phase fraction. Both agents also caused the induction of p53, p21, and p16.
CONCLUSION: The chemopreventive agents 4-HPR and DFMO inhibit leiomyoma cell growth in vitro and induce apoptosis, which implies that retinoids and polyamines are important regulators of leiomyoma growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042000     DOI: 10.1016/j.ajog.2003.09.048

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata.

Authors:  Lauren A Wise; Rose G Radin; Julie R Palmer; Shiriki K Kumanyika; Deborah A Boggs; Lynn Rosenberg
Journal:  Am J Clin Nutr       Date:  2011-11-09       Impact factor: 7.045

2.  Fenretinide: A Potential Treatment for Endometriosis.

Authors:  Mary Ellen Pavone; Saurabh S Malpani; Matthew Dyson; J Julie Kim; Serdar E Bulun
Journal:  Reprod Sci       Date:  2016-02-25       Impact factor: 3.060

3.  Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Authors:  Andrea Decensi; Chris Robertson; Aliana Guerrieri-Gonzaga; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Marcella Gulisano; Harriet Johansson; Viviana Galimberti; Enrico Cassano; Simona M Moroni; Franca Formelli; Ernst A Lien; Giuseppe Pelosi; Karen A Johnson; Bernardo Bonanni
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

4.  The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis.

Authors:  Mary Ann Arndt; Valentina Battaglia; Eva Parisi; Mark J Lortie; Masato Isome; Christopher Baskerville; Donald P Pizzo; Riccardo Ientile; Sebastiano Colombatto; Antonio Toninello; Joseph Satriano
Journal:  Am J Physiol Cell Physiol       Date:  2009-03-25       Impact factor: 4.249

Review 5.  Dietary Natural Compounds and Vitamins as Potential Cofactors in Uterine Fibroids Growth and Development.

Authors:  Iwona Szydłowska; Jolanta Nawrocka-Rutkowska; Agnieszka Brodowska; Aleksandra Marciniak; Andrzej Starczewski; Małgorzata Szczuko
Journal:  Nutrients       Date:  2022-02-09       Impact factor: 5.717

6.  Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells.

Authors:  Minnie Malik; Joy Webb; William H Catherino
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-01       Impact factor: 3.478

7.  Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model.

Authors:  Sandra Durante; Isabella Orienti; Gabriella Teti; Viviana Salvatore; Stefano Focaroli; Anna Tesei; Sara Pignatta; Mirella Falconi
Journal:  Oncotarget       Date:  2014-07-15

8.  Global metabolomic profiling of uterine leiomyomas.

Authors:  Hanna-Riikka Heinonen; Miika Mehine; Netta Mäkinen; Annukka Pasanen; Esa Pitkänen; Auli Karhu; Nanna S Sarvilinna; Jari Sjöberg; Oskari Heikinheimo; Ralf Bützow; Lauri A Aaltonen; Eevi Kaasinen
Journal:  Br J Cancer       Date:  2017-10-26       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.